Arrowstreet Capital
GMAB icon

Arrowstreet Capital’s Genmab GMAB Stock Holding History

Arrowstreet Capital’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Hold
4,975,324
– – 0.06% 275
2026
Q1 		$133M Sell
4,975,324
-2,734
-0.1% -$81.9K 0.07% 259
2025
Q4 		$153M Buy
4,978,058
+1,334,919
+37% +$41.6M 0.09% 224
2025
Q3 		$112M Buy
3,643,139
+188,761
+5% +$4.6M 0.07% 254
2025
Q2 		$71.4M Buy
3,454,378
+2,084,966
+152% +$42.8M 0.05% 336
2025
Q1 		$26.8M Buy
1,369,412
+1,338,972
+4,399% +$28.1M 0.02% 515
2024
Q4 		$635K Sell
30,440
-63,188
-67% -$1.39M ﹤0.01% 1536
2024
Q3 		$341K Buy
93,628
+56,219
+150% +$1.5M ﹤0.01% 1577
2024
Q2 		$940K Buy
+37,409
New +$1.06M ﹤0.01% 1230
2023
Q2 		– Sell
-1,014,533
Closed -$38.3M – 1320
2023
Q1 		$38.3M Sell
1,014,533
-740,684
-42% -$28.5M 0.05% 311
2022
Q4 		$74.4M Buy
1,755,217
+269,691
+18% +$11.1M 0.1% 187
2022
Q3 		$47.7M Buy
1,485,526
+190,807
+15% +$6.7M 0.07% 236
2022
Q2 		$42.1M Buy
1,294,719
+425,498
+49% +$13.8M 0.06% 247
2022
Q1 		$31.4M Buy
869,221
+338,902
+64% +$11.6M 0.04% 331
2021
Q4 		$21M Buy
530,319
+102,620
+24% +$4.28M 0.03% 460
2021
Q3 		$18.7M Buy
427,699
+418,099
+4,355% +$18.8M 0.02% 553
2021
Q2 		$392K Sell
9,600
-90,033
-90% -$3.47M ﹤0.01% 1713
2021
Q1 		$3.27M Sell
99,633
-286,067
-74% -$10.8M ﹤0.01% 1359
2020
Q4 		$15.7M Sell
385,700
-93,895
-20% -$3.51M 0.02% 684
2020
Q3 		$17.6M Sell
479,595
-250,174
-34% -$9.05M 0.03% 604
2020
Q2 		$24.7M Buy
729,769
+51,467
+8% +$1.4M 0.05% 422
2020
Q1 		$14.4M Buy
678,302
+328,880
+94% +$7.33M 0.04% 381
2019
Q4 		$7.8M Buy
349,422
+244,317
+232% +$5.33M 0.02% 694
2019
Q3 		$2.13M Buy
+105,105
New +$2.07M 0.01% 968

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Arrowstreet Capital's GMAB Position: Q2 2026 in Review

Arrowstreet Capital held its Genmab (GMAB) position steady in Q2 2026 at 4,975,324 shares worth $137M. The position accounts for 0.06% of the portfolio, ranked #275.

Arrowstreet Capital first reported a position in GMAB in Q3 2019 and has held it in 24 quarters since. The position peaked at $153M in Q4 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Arrowstreet Capital held 4,975,324 shares of Genmab worth $137M as of Q2 2026.
  • Arrowstreet Capital left its Genmab share count unchanged in Q2 2026.
  • Genmab made up 0.06% of Arrowstreet Capital's portfolio in Q2 2026, its #275 holding.
  • Arrowstreet Capital first reported a position in Genmab in Q3 2019 and has held it in 24 quarters since.
  • Arrowstreet Capital's Genmab position peaked at $153M in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.